Small Lymphocytic Lymphoma (SLL)

Patients with treatment-naive CLL/SLL experienced long-term improved efficacy when treated with Brukinsa compared with bendamustine plus Rituxan.

When I am triggered by something related to the cancer I have, I start going down a negative rabbit hole but remind myself to be vigilant when this happens.

My quality of life has improved a lot after starting on a BTK inhibitor, but some things will never be the same — like being in crowded places without a mask!

After recently losing my aunt, I realized that cancer has given me a new perspective on life, which reminds me that every day has meaning.

Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic lymphocytic leukemia.

Living with chronic small lymphocytic lymphoma for the past 15 years has taught me some very valuable lessons, from dieting to managing anxiety.

The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.

After having SLL for 15 years, I won't let it define me — now, I'm working towards larger passions in my life.

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma tended to be more likely to stay on treatment and experience fewer heart toxicities with Calquence or Brukinsa.

After reading a book about how Imbruvica was revolutionized for SLL and CLL, I now have a greater appreciation for the drugs I receive.

When my doctor told me, "I want to talk to you about something," I suddenly felt worried — thankfully it was good news.

For 14 years, I've been dealing with small lymphocytic lymphoma, and want to maintain a healthier diet.

My faith has helped guide me through chronic small lymphocytic lymphoma.

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

I've been living with small lymphocytic lymphoma for 14 years now, but it has taught be some valuable lessons about life.

Certain antihypertensive medications may lower blood pressure in patients with blood cancer being treated with Imbruvica or other BTK inhibitors.

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

BTK degrader NX-5948 has been granted Fast Track designation by the FDA to treat some adults with relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic lymphoma.

Before my biopsy, the doctor assured me it was nothing. He said he was just doing this to prove it to me. We definitely didn’t expect what followed next.

I only allow anxiety to take up 15 minutes of my days.

“I flow, I change constantly, I am my grief, I am my joy, I am human, I am divine light, I can submerge when I make the time.” — Shosh Madick.

I am so happy that I was able to celebrate my wedding anniversary with my biggest supporter.

CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

After being diagnosed with an incurable cancer, I had to reframe my thinking to focus on the positive.

Bruton tyrosine kinase inhibitors have changed the space for treating patients with CLL or SLL, with more on the way to potentially address drug resistance.

I was optimistic about my lymphoma diagnosis and new treatment plan when a lump was found after I underwent a mammogram.

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

After being diagnosed with lymphoma, I scheduled consultations with three oncologists, but only one provided me with the hope I needed.

In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.